Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

In an announcement Monday, Nov. 3, the Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and other oral medicines. Lilly expects to ...

Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to Lilly Gateway Labs (LGL) ...

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up ...

Eli Lilly continues to do what it does best, which is to capture the obesity and type 2 diabetes treatment markets at an extremely rapid pace. So, sales of its flagship franchise called tirzepatide ...